Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
40
RAPT Quote, Financials, Valuation and Earnings
Last price:
$10.31
Seasonality move
:
-6.61%
Day range:
$10.26 - $10.95
52-week range:
$5.67 - $30.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
34.39x
P/B ratio:
0.98x
Volume:
102.1K
Avg. volume:
117.4K
1-year change:
-64.93%
Market cap:
$174M
Revenue:
--
EPS (TTM):
-$19.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RAPT
RAPT Therapeutics
|
-- | -$0.64 | -- | -88.73% | $24.75 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.35 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RAPT
RAPT Therapeutics
|
$10.52 | $24.75 | $174M | -- | $0.00 | 0% | 34.39x |
|
ATNM
Actinium Pharmaceuticals
|
$1.59 | $5.00 | $49.6M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.60 | -- | $25.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.42 | $1.00 | $1M | -- | $0.00 | 0% | 0.45x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RAPT
RAPT Therapeutics
|
-- | -2.490 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.037 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RAPT
RAPT Therapeutics
|
-- | -$19.3M | -- | -- | -- | -$52.5M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
RAPT Therapeutics vs. Competitors
-
Which has Higher Returns RAPT or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to RAPT Therapeutics's net margin of -11511.11%. RAPT Therapeutics's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital RAPTRAPT Therapeutics-- -$0.64 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About RAPT or ATNM?
RAPT Therapeutics has a consensus price target of $24.75, signalling upside risk potential of 135.27%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 214.47%. Given that Actinium Pharmaceuticals has higher upside potential than RAPT Therapeutics, analysts believe Actinium Pharmaceuticals is more attractive than RAPT Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RAPTRAPT Therapeutics1 3 0 ATNMActinium Pharmaceuticals2 1 0 -
Is RAPT or ATNM More Risky?
RAPT Therapeutics has a beta of -0.093, which suggesting that the stock is 109.328% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.
-
Which is a Better Dividend Stock RAPT or ATNM?
RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPT or ATNM?
RAPT Therapeutics quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. RAPT Therapeutics's net income of -$17.2M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 34.39x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPTRAPT Therapeutics34.39x -- -- -$17.2M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns RAPT or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to RAPT Therapeutics's net margin of -49.65%. RAPT Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital RAPTRAPT Therapeutics-- -$0.64 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About RAPT or NBY?
RAPT Therapeutics has a consensus price target of $24.75, signalling upside risk potential of 135.27%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that RAPT Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe RAPT Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings RAPTRAPT Therapeutics1 3 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is RAPT or NBY More Risky?
RAPT Therapeutics has a beta of -0.093, which suggesting that the stock is 109.328% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock RAPT or NBY?
RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPT or NBY?
RAPT Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. RAPT Therapeutics's net income of -$17.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 34.39x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPTRAPT Therapeutics34.39x -- -- -$17.2M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns RAPT or NNVC?
Nanoviricides has a net margin of -- compared to RAPT Therapeutics's net margin of --. RAPT Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RAPTRAPT Therapeutics-- -$0.64 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About RAPT or NNVC?
RAPT Therapeutics has a consensus price target of $24.75, signalling upside risk potential of 135.27%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Nanoviricides has higher upside potential than RAPT Therapeutics, analysts believe Nanoviricides is more attractive than RAPT Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RAPTRAPT Therapeutics1 3 0 NNVCNanoviricides0 0 0 -
Is RAPT or NNVC More Risky?
RAPT Therapeutics has a beta of -0.093, which suggesting that the stock is 109.328% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock RAPT or NNVC?
RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPT or NNVC?
RAPT Therapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. RAPT Therapeutics's net income of -$17.2M is lower than Nanoviricides's net income of -$2.2M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 34.39x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPTRAPT Therapeutics34.39x -- -- -$17.2M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns RAPT or OGEN?
Oragenics has a net margin of -- compared to RAPT Therapeutics's net margin of --. RAPT Therapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RAPTRAPT Therapeutics-- -$0.64 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About RAPT or OGEN?
RAPT Therapeutics has a consensus price target of $24.75, signalling upside risk potential of 135.27%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than RAPT Therapeutics, analysts believe Oragenics is more attractive than RAPT Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RAPTRAPT Therapeutics1 3 0 OGENOragenics0 1 0 -
Is RAPT or OGEN More Risky?
RAPT Therapeutics has a beta of -0.093, which suggesting that the stock is 109.328% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock RAPT or OGEN?
RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPT or OGEN?
RAPT Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. RAPT Therapeutics's net income of -$17.2M is lower than Oragenics's net income of -$2.2M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 34.39x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPTRAPT Therapeutics34.39x -- -- -$17.2M OGENOragenics0.45x -- -- -$2.2M
-
Which has Higher Returns RAPT or TOVX?
Theriva Biologics has a net margin of -- compared to RAPT Therapeutics's net margin of --. RAPT Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RAPTRAPT Therapeutics-- -$0.64 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About RAPT or TOVX?
RAPT Therapeutics has a consensus price target of $24.75, signalling upside risk potential of 135.27%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than RAPT Therapeutics, analysts believe Theriva Biologics is more attractive than RAPT Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RAPTRAPT Therapeutics1 3 0 TOVXTheriva Biologics1 1 0 -
Is RAPT or TOVX More Risky?
RAPT Therapeutics has a beta of -0.093, which suggesting that the stock is 109.328% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock RAPT or TOVX?
RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPT or TOVX?
RAPT Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. RAPT Therapeutics's net income of -$17.2M is lower than Theriva Biologics's net income of -$4.3M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 34.39x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPTRAPT Therapeutics34.39x -- -- -$17.2M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
